Praxis Precision Medicines, Inc. (PRAX)
- Previous Close
52.88 - Open
52.86 - Bid 54.61 x 200
- Ask 55.12 x 100
- Day's Range
51.80 - 56.42 - 52 Week Range
12.45 - 67.21 - Volume
133,868 - Avg. Volume
203,295 - Market Cap (intraday)
936.417M - Beta (5Y Monthly) 2.90
- PE Ratio (TTM)
-- - EPS (TTM)
-18.69 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
138.60
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
praxismedicines.comRecent News: PRAX
Performance Overview: PRAX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRAX
Valuation Measures
Market Cap
936.42M
Enterprise Value
857.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
147.68
Price/Book (mrq)
13.44
Enterprise Value/Revenue
350.47
Enterprise Value/EBITDA
-6.81
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-77.79%
Return on Equity (ttm)
-169.13%
Revenue (ttm)
2.45M
Net Income Avi to Common (ttm)
-123.28M
Diluted EPS (ttm)
-18.69
Balance Sheet and Cash Flow
Total Cash (mrq)
81.3M
Total Debt/Equity (mrq)
3.58%
Levered Free Cash Flow (ttm)
-65.69M